image
Sangamo Therapeutics, Inc. SGMO
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 2.05
-4.65 %
$ 428 M
Market Cap
-1.68
P/E
1. INTRINSIC VALUE

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease.[ Read More ]

The intrinsic value of one SGMO stock under the base case scenario is HIDDEN Compared to the current market price of 2.05 USD, Sangamo Therapeutics, Inc. is HIDDEN

SGMO Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart SGMO

image
FINANCIALS
176 M REVENUE
58.34%
Growth Rates
1Year 58.34%
3Years 14.24%
5Years 15.85%
7Years 37.07%
10Years 22.00%
-274 M OPERATING INCOME
-36.13%
Growth Rates
1Year -36.13%
3Years -28.36%
5Years -28.85%
7Years -20.90%
10Years -26.22%
-258 M NET INCOME
-34.09%
Growth Rates
1Year -34.09%
3Years -28.64%
5Years -30.21%
7Years -20.07%
10Years -25.49%
-225 M OPERATING CASH FLOW
-0.54%
Growth Rates
1Year -0.54%
3Years -32.45%
5Years -47.80%
7Years -19.17%
10Years -27.71%
154 M INVESTING CASH FLOW
158.97%
Growth Rates
1Year 158.97%
3Years 36.89%
5Years 23.41%
7Years 35.69%
10Years 15.58%
14.6 M FINANCING CASH FLOW
-82.77%
Growth Rates
1Year -82.77%
3Years -54.33%
5Years -42.48%
7Years 71.30%
10Years -15.23%
49.4 M REVENUE
13779.78%
Growth Rates
1Year 58.34%
3Years 14.24%
5Years 15.85%
7Years 37.07%
10Years 22.00%
10.6 M OPERATING INCOME
128.67%
Growth Rates
1Year -36.13%
3Years -28.36%
5Years -28.85%
7Years -20.90%
10Years -26.22%
10.7 M NET INCOME
129.54%
Growth Rates
1Year -34.09%
3Years -28.64%
5Years -30.21%
7Years -20.07%
10Years -25.49%
11.8 M OPERATING CASH FLOW
143.74%
Growth Rates
1Year -0.54%
3Years -32.45%
5Years -47.80%
7Years -19.17%
10Years -27.71%
233 K INVESTING CASH FLOW
83.46%
Growth Rates
1Year 158.97%
3Years 36.89%
5Years 23.41%
7Years 35.69%
10Years 15.58%
-203 K FINANCING CASH FLOW
61.91%
Growth Rates
1Year -82.77%
3Years -54.33%
5Years -42.48%
7Years 71.30%
10Years -15.23%
Balance Sheet Decomposition Sangamo Therapeutics, Inc.
image
Current Assets 94.3 M
Cash & Short-Term Investments 81 M
Receivables 1.33 M
Other Current Assets 12 M
Non-Current Assets 71 M
Long-Term Investments 0
PP&E 52.9 M
Other Non-Current Assets 18.1 M
Current Liabilities 47.7 M
Accounts Payable 15.3 M
Short-Term Debt 4.59 M
Other Current Liabilities 27.9 M
Non-Current Liabilities 34.7 M
Long-Term Debt 33.5 M
Other Non-Current Liabilities 1.19 M
EFFICIENCY
Earnings Waterfall Sangamo Therapeutics, Inc.
image
Revenue 176 M
Cost Of Revenue 222 M
Gross Profit -45.3 M
Operating Expenses 229 M
Operating Income -274 M
Other Expenses -16.2 M
Net Income -258 M
RATIOS
-25.72% GROSS MARGIN
-25.72%
Averages
1Year -25.72%
3Years 51.63%
5Years 11.91%
7Years -8.03%
10Years -38.81%
-155.48% OPERATING MARGIN
-155.48%
Averages
1Year -155.48%
3Years -167.31%
5Years -142.85%
7Years -137.10%
10Years -151.08%
-146.30% NET MARGIN
-146.30%
Averages
1Year -146.30%
3Years -160.04%
5Years -131.32%
7Years -126.68%
10Years -141.69%
-311.06% ROE
-311.06%
Averages
1Year -311.06%
3Years -141.25%
5Years -93.13%
7Years -73.33%
10Years -59.99%
-155.96% ROA
-155.96%
Averages
1Year -155.96%
3Years -71.61%
5Years -47.93%
7Years -38.61%
10Years -34.52%
-324.20% ROIC
-324.20%
Averages
1Year -324.20%
3Years -147.17%
5Years -97.39%
7Years -77.10%
10Years -62.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sangamo Therapeutics, Inc.
image
Net Income -258 M
Depreciation & Amortization 22.2 M
Capital Expenditures -21.2 M
Stock-Based Compensation 27.4 M
Change in Working Capital -164 M
Others -19 M
Free Cash Flow -246 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sangamo Therapeutics, Inc.
image
SGMO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

image
0.00115 USD
EDIT
Overvalued 99.96%

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

image
-5.07 USD
NTLA
Overvalued 136.26%

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

image
9.25 USD
BLUE
Undervalued 2784.01%

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

image
214 USD
ALNY
Overvalued 9.25%
6. Ownership
Insider Ownership Sangamo Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 26, 2023
Sell 3 M USD
BIOGEN INC.
10 percent owner
- 6000000
 0.5 USD
2 years ago
Aug 29, 2022
Sell 2.13 M USD
Biogen MA Inc.
director:
- 400000
 5.3268 USD
2 years ago
Aug 29, 2022
Sell 2.13 M USD
BIOGEN INC.
10 percent owner
- 400000
 5.3268 USD
2 years ago
Aug 30, 2022
Sell 527 K USD
BIOGEN INC.
10 percent owner
- 100000
 5.2652 USD
2 years ago
Aug 29, 2022
Sell 527 K USD
Biogen MA Inc.
director:
- 100000
 5.2652 USD
2 years ago
Jun 03, 2022
Bought 25 K USD
Markels John
director:
+ 6784
 3.6894 USD
2 years ago
Jun 01, 2022
Bought 18 K USD
PARKER H STEWART
director:
+ 5000
 3.5992 USD
2 years ago
Dec 28, 2021
Sell 23.5 K USD
BIOGEN INC.
10 percent owner
- 2764
 8.5101 USD
2 years ago
Dec 23, 2021
Sell 695 K USD
BIOGEN INC.
10 percent owner
- 81187
 8.5547 USD
2 years ago
Dec 27, 2021
Sell 5.14 K USD
BIOGEN INC.
10 percent owner
- 600
 8.56 USD
2 years ago
Dec 09, 2021
Sell 203 K USD
BIOGEN INC.
10 percent owner
- 23660
 8.5605 USD
2 years ago
Dec 07, 2021
Sell 444 K USD
BIOGEN INC.
10 percent owner
- 52178
 8.5177 USD
2 years ago
Dec 08, 2021
Sell 655 K USD
BIOGEN INC.
10 percent owner
- 75814
 8.6373 USD
2 years ago
Dec 01, 2021
Sell 6.22 K USD
BIOGEN INC.
10 percent owner
- 730
 8.5249 USD
2 years ago
Dec 02, 2021
Sell 15.9 K USD
BIOGEN INC.
10 percent owner
- 1874
 8.5074 USD
2 years ago
Nov 26, 2021
Sell 248 K USD
BIOGEN INC.
10 percent owner
- 28884
 8.6011 USD
3 years ago
Mar 23, 2021
Sell 157 K USD
LOEB GARY
EVP, General Counsel & Sec.
- 11981
 13.1032 USD
3 years ago
Mar 23, 2021
Sell 65.9 K USD
LOEB GARY
EVP, General Counsel & Sec.
- 5000
 13.1801 USD
3 years ago
Mar 23, 2021
Sell 7.15 K USD
LOEB GARY
EVP, General Counsel & Sec.
- 543
 13.1713 USD
3 years ago
Dec 31, 2020
Sell 41.2 K USD
Ramelmeier Rolf Andrew
EVP, Technical Operations
- 2464
 16.74 USD
3 years ago
Dec 24, 2020
Sell 60.4 K USD
Ramelmeier Rolf Andrew
EVP, Technical Operations
- 3331
 18.13 USD
3 years ago
Dec 17, 2020
Sell 133 K USD
Ramasastry Saira
Director
- 10000
 13.2747 USD
4 years ago
Mar 19, 2020
Sell 210 K USD
DILLY STEPHEN GEORGE
Director
- 35000
 6 USD
4 years ago
Mar 18, 2020
Bought 15.6 K USD
PARKER H STEWART
Director
+ 3000
 5.195 USD
4 years ago
Mar 17, 2020
Bought 25 K USD
Zakrzewski Joseph S
Director
+ 5000
 4.99 USD
4 years ago
Mar 16, 2020
Sell 90.3 K USD
DILLY STEPHEN GEORGE
Director
- 15000
 6.0174 USD
4 years ago
Mar 13, 2020
Bought 28.4 K USD
Zakrzewski Joseph S
Director
+ 5000
 5.67 USD
4 years ago
Mar 12, 2020
Bought 94.6 K USD
Zakrzewski Joseph S
Director
+ 15000
 6.31 USD
5 years ago
May 15, 2019
Sell 50 K USD
Yi Kathy
EVP & Chief Financial Officer
- 5000
 10 USD
5 years ago
Apr 15, 2019
Sell 60.6 K USD
Yi Kathy
EVP & Chief Financial Officer
- 5000
 12.11 USD
5 years ago
Mar 15, 2019
Sell 50 K USD
Yi Kathy
EVP & Chief Financial Officer
- 5000
 10 USD
5 years ago
Mar 01, 2019
Sell 50 K USD
Yi Kathy
EVP & Chief Financial Officer
- 5000
 10 USD
5 years ago
Jan 15, 2019
Sell 55.2 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 11.04 USD
5 years ago
Jan 07, 2019
Sell 61.6 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 12.3261 USD
5 years ago
Dec 17, 2018
Sell 57.2 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 11.44 USD
5 years ago
Dec 06, 2018
Sell 57.4 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 11.4866 USD
6 years ago
Nov 15, 2018
Sell 50 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 10 USD
6 years ago
Nov 14, 2018
Bought 18 K USD
PARKER H STEWART
Director
+ 2000
 9.0008 USD
6 years ago
Nov 06, 2018
Sell 68.6 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 13.73 USD
6 years ago
Oct 15, 2018
Sell 69.8 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 13.97 USD
6 years ago
Oct 08, 2018
Sell 72.8 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 14.5547 USD
6 years ago
Sep 17, 2018
Sell 73.3 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 14.6569 USD
6 years ago
Sep 07, 2018
Bought 100 K USD
JEFFS ROGER
Director
+ 7408
 13.5646 USD
6 years ago
Sep 07, 2018
Bought 27 K USD
PARKER H STEWART
Director
+ 2000
 13.52 USD
6 years ago
Sep 06, 2018
Sell 70.8 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 14.169 USD
6 years ago
Aug 16, 2018
Sell 77 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 15.3903 USD
6 years ago
Aug 06, 2018
Sell 67.2 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 13.45 USD
6 years ago
Jul 16, 2018
Sell 73.9 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 14.772 USD
6 years ago
Jul 06, 2018
Sell 79 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 15.795 USD
6 years ago
Jun 15, 2018
Sell 78.4 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 15.673 USD
6 years ago
Jun 06, 2018
Sell 83.4 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 16.67 USD
6 years ago
May 15, 2018
Sell 76.9 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 15.384 USD
6 years ago
May 07, 2018
Sell 81.8 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 16.3628 USD
6 years ago
Apr 16, 2018
Sell 99.1 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 19.8288 USD
6 years ago
Apr 13, 2018
Sell 163 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 8163
 20 USD
6 years ago
Apr 06, 2018
Sell 87.1 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 17.413 USD
6 years ago
Apr 02, 2018
Sell 131 K USD
Mento Steven J
Director
- 7115
 18.3933 USD
6 years ago
Apr 02, 2018
Sell 1.89 K USD
Mento Steven J
Director
- 100
 18.9 USD
6 years ago
Apr 02, 2018
Sell 41.7 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 2278
 18.2984 USD
6 years ago
Mar 15, 2018
Sell 128 K USD
Yi Kathy
SVP & Chief Financial Officer
- 5000
 25.5624 USD
6 years ago
Mar 06, 2018
Sell 124 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 24.7755 USD
6 years ago
Mar 01, 2018
Sell 220 K USD
Mento Steven J
Director
- 9433
 23.2743 USD
6 years ago
Mar 01, 2018
Sell 346 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 15000
 23.0574 USD
6 years ago
Feb 26, 2018
Sell 235 K USD
Ramasastry Saira
Director
- 9450
 24.8762 USD
6 years ago
Feb 06, 2018
Sell 92.4 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 18.4871 USD
6 years ago
Feb 01, 2018
Sell 237 K USD
Mento Steven J
Director
- 11520
 20.5867 USD
6 years ago
Feb 01, 2018
Sell 309 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 15000
 20.5903 USD
6 years ago
Jan 08, 2018
Sell 85.5 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 17.109 USD
6 years ago
Jan 02, 2018
Sell 114 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 6974
 16.35 USD
6 years ago
Jan 03, 2018
Sell 145 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 8026
 18.05 USD
6 years ago
Dec 06, 2017
Sell 81.2 K USD
Conner Edward R.
Sr. VP & Chief Medical Officer
- 5000
 16.24 USD
6 years ago
Dec 04, 2017
Sell 212 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 11803
 18 USD
6 years ago
Nov 30, 2017
Sell 215 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 13433
 16 USD
6 years ago
Dec 01, 2017
Sell 53.4 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 3197
 16.7 USD
6 years ago
Nov 30, 2017
Sell 215 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 13433
 16 USD
6 years ago
Dec 01, 2017
Sell 53.4 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 3197
 16.7 USD
7 years ago
Nov 17, 2017
Sell 73.3 K USD
Ramasastry Saira
Director
- 5000
 14.6678 USD
7 years ago
Oct 02, 2017
Sell 81.2 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 5416
 15 USD
7 years ago
Oct 02, 2017
Sell 60.1 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 3754
 16 USD
7 years ago
Sep 20, 2017
Sell 446 K USD
RINGO WILLIAM R
Director
- 31000
 14.3741 USD
7 years ago
Sep 01, 2017
Sell 155 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 10316
 15 USD
7 years ago
Aug 14, 2017
Sell 55 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 5000
 11 USD
7 years ago
Aug 11, 2017
Sell 64.7 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 6474
 10 USD
7 years ago
Jul 14, 2017
Sell 1.72 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 172
 10 USD
7 years ago
Jul 14, 2017
Sell 148 K USD
Herberts Curt A. III
Sr.VP & Chief Business Officer
- 14828
 10 USD
7. News
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript seekingalpha.com - 4 days ago
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago. zacks.com - 4 days ago
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 CONFERENCE CALL AND WEBCAST. businesswire.com - 1 week ago
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approval. The global Fabry Disease treatment market size is expected to be worth $3.34 billion by 2030. Data from the phase 1/2 STARR study, using isaralgagene civaparvovec targeting patients with Fabry Disease, is expected in the first half of 2025. seekingalpha.com - 3 weeks ago
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025. businesswire.com - 3 weeks ago
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors. seekingalpha.com - 3 weeks ago
3 Penny Stocks To Buy With Just $750 Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky. 247wallst.com - 1 month ago
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants Nicole Germino - Truist Securities Gena Wang - Barclays Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Lisa Walter - RBC Operator Good afternoon, and welcome to the Sangamo Therapeutics Second Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded. seekingalpha.com - 3 months ago
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago. zacks.com - 3 months ago
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today? Sangamo Therapeutics (NASDAQ: SGMO ) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat certain neurodegenerative diseases. investorplace.com - 3 months ago
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today? When small-cap biotech stocks go on a tear, many investors pay attention. Little-known company Sangamo Therapeutics (NASDAQ: SGMO ) is making waves today, with SGMO stock up more than 40% at the time of this writing. investorplace.com - 3 months ago
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues. benzinga.com - 3 months ago
8. Profile Summary

Sangamo Therapeutics, Inc. SGMO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 428 M
Dividend Yield 0.00%
Description Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Contact 501 Canal Blvd, Brisbane California, CALIFORNIA, 94005 https://www.sangamo.com
IPO Date April 6, 2000
Employees 405
Officers Dr. Nathalie Dubois-Stringfellow Ph.D. Senior Vice President & Chief Development Officer Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. Chief Executive Officer, President & Director Ms. Prathyusha Duraibabu CPA, M.B.A. Senior Vice President, Chief Financial Officer & Principal Accounting Officer